Theravance Biopharma, Inc. Total Long-Term Debt
Theravance Biopharma, Inc. (TBPH) had Total Long-Term Debt of $0 as of 2023-12-31, per its 10-K filed 2024-03-01.
Discontinued › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2024-03-01
- 2023-12-31: Long-term Debt $0.00.
- 2022-06-30: Long-term Debt $624.70M.
- 2022-03-31: Long-term Debt $621.48M.
- 2021-12-31: Long-term Debt $616.33M.
| Period end | Long-term Debt |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-01 |
| 2022-06-30 | $624.70M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $621.48M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $616.33M 10-K · filed 2023-03-01 |
| 2021-09-30 | $615.87M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $609.51M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $614.07M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $619.17M 10-K · filed 2022-02-28 |
| 2019-12-31 | $455.04M 10-K · filed 2021-02-26 |
| 2018-12-31 | $454.35M 10-K · filed 2020-02-27 |
| 2017-12-31 | $223.75M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |